ECSP21080966A - Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 - Google Patents

Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Info

Publication number
ECSP21080966A
ECSP21080966A ECSENADI202180966A ECDI202180966A ECSP21080966A EC SP21080966 A ECSP21080966 A EC SP21080966A EC SENADI202180966 A ECSENADI202180966 A EC SENADI202180966A EC DI202180966 A ECDI202180966 A EC DI202180966A EC SP21080966 A ECSP21080966 A EC SP21080966A
Authority
EC
Ecuador
Prior art keywords
mrgx2
thiadiazine
benzo
inhibitors
amino
Prior art date
Application number
ECSENADI202180966A
Other languages
English (en)
Inventor
Tony Gibson
Angie Vassar
Mitsunori Kono
Steve Swann
Feng Zhou
Allison Chambers
Masaki Seto
Zenyu Shiokawa
Jason Pickens
Simone Bigi
Original Assignee
Solent Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solent Therapeutics Llc filed Critical Solent Therapeutics Llc
Publication of ECSP21080966A publication Critical patent/ECSP21080966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Se describen compuestos de la Fórmula 1, tautómeros de los mismos, y sales farmacéuticamente aceptables de los compuestos o tautómeros, en donde L, R1, R2, R3, R4 y R5 son definidos en la especificación. Esta descripción también se refiere a materiales y métodos para preparar compuestos de la Fórmula 1, a las composiciones farmacéuticas que las contienen, y a su uso para tratar enfermedades, trastornos o afecciones asociadas con MRGX2.
ECSENADI202180966A 2019-04-29 2021-11-15 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 ECSP21080966A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962840344P 2019-04-29 2019-04-29

Publications (1)

Publication Number Publication Date
ECSP21080966A true ECSP21080966A (es) 2022-01-31

Family

ID=70779887

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180966A ECSP21080966A (es) 2019-04-29 2021-11-15 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Country Status (22)

Country Link
US (1) US20220119361A1 (es)
EP (1) EP3962901A1 (es)
JP (1) JP2022535672A (es)
KR (1) KR20220012244A (es)
CN (1) CN114072393A (es)
AR (1) AR119728A1 (es)
AU (1) AU2020266529A1 (es)
BR (1) BR112021021508A2 (es)
CA (1) CA3137584A1 (es)
CL (1) CL2021002805A1 (es)
CO (1) CO2021014155A2 (es)
CR (1) CR20210544A (es)
DO (1) DOP2021000223A (es)
EC (1) ECSP21080966A (es)
IL (1) IL287521A (es)
JO (1) JOP20210275A1 (es)
MA (1) MA55804A (es)
MX (1) MX2021013135A (es)
PE (1) PE20220425A1 (es)
SG (1) SG11202111717XA (es)
TW (1) TW202106669A (es)
WO (1) WO2020223255A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
WO2022152853A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2022152852A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20060217370A1 (en) * 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
WO2008052072A2 (en) * 2006-10-24 2008-05-02 Acadia Pharmaceuticals Inc. Compounds for the treatment of pain and screening methods therefor

Also Published As

Publication number Publication date
BR112021021508A2 (pt) 2022-03-22
AR119728A1 (es) 2022-01-05
CN114072393A (zh) 2022-02-18
KR20220012244A (ko) 2022-02-03
CA3137584A1 (en) 2020-11-05
WO2020223255A1 (en) 2020-11-05
US20220119361A1 (en) 2022-04-21
CO2021014155A2 (es) 2021-10-29
MA55804A (fr) 2022-04-06
AU2020266529A1 (en) 2021-12-16
CL2021002805A1 (es) 2022-07-22
MX2021013135A (es) 2021-11-25
DOP2021000223A (es) 2022-01-16
TW202106669A (zh) 2021-02-16
EP3962901A1 (en) 2022-03-09
PE20220425A1 (es) 2022-03-29
JP2022535672A (ja) 2022-08-10
JOP20210275A1 (ar) 2023-01-30
IL287521A (en) 2021-12-01
SG11202111717XA (en) 2021-11-29
CR20210544A (es) 2022-03-30

Similar Documents

Publication Publication Date Title
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
CO2022000480A2 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
PE20050089A1 (es) Derivados de azo [1,2-c] quinazolina condensados
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
UY35376A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
UY28738A1 (es) Deridos 1h-tieno(2,3-c)pirazol útiles como inhibidores de quinasa
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
ECSP099046A (es) Derivados ciclopropil amina
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY39517A (es) Inhibidores de la btk
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
ECSP18056196A (es) Derivados de indano
CO2021000782A2 (es) Agentes inhibidores de ask1
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.